Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 7/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | CKS1B | P61024 | 1/20 | 0.42 |
| ▸ | SKP1 | P63208 | 1/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | USP14 | P54578 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11908333 | 0.83 | KMT2A (0.42) | MEN1KMT2A | |
| SCHEMBL1581610 | 0.78 | CHRM2 (0.42) | CKS1BSKP1SKP2 | |
| SCHEMBL26665267 | 0.77 | KCNA3 (0.57) | KCNA3DRD2DRD3CCR5CTSK | |
| SCHEMBL30401098 | 0.76 | KCNA3 (0.55) | KCNA3DRD2DRD3CCR5MEN1 | |
| SCHEMBL26640819 | 0.76 | KCNA3 (0.50) | KCNA3DRD2DRD3CCR5CKS1B | |
| SCHEMBL3956906 | 0.76 | JAK1 (0.45) | DRD2DRD3CKS1BSKP1SKP2 | |
| SCHEMBL915957 | 0.76 | KCNA3 (0.56) | KCNA3DRD2DRD3CCR5CTSK | |
| SCHEMBL913704 | 0.76 | KCNA3 (0.56) | KCNA3DRD2DRD3CCR5CKS1B | |
| SCHEMBL913264 | 0.76 | KCNA3 (0.56) | KCNA3DRD2DRD3CCR5CTSK | |
| SCHEMBL15133835 | 0.76 | MET (0.45) | KCNA3DRD2DRD3CCR5CKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697725-B2 | Tetrahydroquinoline derivatives and their pharmaceutical use | GLAXOSMITHKLINE LLC (US) | 2014-04-15 | — | — | US | disclosed |
| US-20120208798-A1 | Tetrahydroquinoline Derivatives And Their Pharmaceutical Use | GLAXOSMITHKLINE LLC | 2012-08-16 | — | — | US | disclosed |
| WO-2011054841-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208798-A1 | Tetrahydroquinoline Derivatives And Their Pharmaceutical Use | ABCB1, CYP3A7, UGT2B7 | KCNA3 993/4885DRD2 488/4885DRD3 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.